Study of immune responses in combined treatment with Gemcitabine and Gvax vaccine in murine model
碩士 === 長庚大學 === 生物醫學研究所 === 106 === Gemcitabine (Gem), a kind of deoxycytidine analog nucleoside, is used as the second-line chemotherapy in many cancer. During DNA synthesis, Gemcitabine is incorporated into the new strand. This leads the cell to inhibit the DNA synthesis and apoptosis. In previous...
Main Authors: | Yu Xin Xie, 謝育昕 |
---|---|
Other Authors: | J. T. Qiu |
Format: | Others |
Language: | en_US |
Published: |
2018
|
Online Access: | http://ndltd.ncl.edu.tw/handle/r8g7vp |
Similar Items
-
The Effects of Cyclophosphamide and GVAX Vaccine Combined Treatment for Cervical Cancer Model
by: Shang Ting Su, et al.
Published: (2019) -
Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma
by: Nusrat Jahan, et al.
Published: (2019-05-01) -
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
by: Mark Yarchoan, et al.
Published: (2020-02-01) -
Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer
by: Soeren M. Buchholz, et al.
Published: (2020-07-01) -
Antitumor efficacy of combination of interferon-gamma-inducible protein 10 gene with gemcitabine, a study in murine model
by: Zhang Zhixuan, et al.
Published: (2008-11-01)